FORM 10-Q


                       Securities and Exchange Commission
                             Washington, D. C. 20549

           (Mark One)
               X       Quarterly   Report  Pursuant  to
                           Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                      For Quarter Ended: November 30, 1999
                                       OR
                _  Transition Report Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

                         Commission File Number: 0-14820

                                  IMMUCOR, INC.
             (Exact name of registrant as specified in its charter)


                 Georgia                                22-2408354
      (State or other jurisdiction of                 (I.R.S. Employer
        incorporation or organization)               Identification No.)

        3130 Gateway Drive P.O. Box 5625 Norcross, Georgia   30091-5625
          (Address of principal executive offices)           (Zip Code)


                  Registrant's telephone number: (770) 441-2051

     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                                 Yes X    No

     Indicate the number of shares  outstanding of each of the issuer's  classes
of common stock, as of the latest practicable date.

        As of January 3, 2000: Common Stock, $. 10 Par Value - 7,790,930

<PAGE>


                                 IMMUCOR, INC.
                      Condensed Consolidated Balance Sheets

                                            November 30, 1999      May 31, 1999
ASSETS                                         (Unaudited)          (Audited)
                                             ---------------      --------------
Current assets:
    Cash and cash equivalents                   $ 2,993,923         $ 2,793,592
    Accounts receivable, net                     23,907,672          21,573,846
    Accounts receivable from
          former officer and director                     -             140,946
    Inventories                                  17,913,479          16,065,190
    Income taxes receivable                         373,418             553,451
    Deferred income taxes                           926,771             907,530
    Prepaid expenses and other                    1,645,680           1,587,817
                                             ---------------      --------------
        Total current assets                     47,760,943          43,622,372

Long-term investment, at cost                     1,000,000           1,000,000

Property and equipment, at cost                  21,092,389          20,195,158
    less accumulated depreciation                (6,364,084)         (5,068,996)
                                             ---------------      --------------
                                                 14,728,305          15,126,162

Deferred income taxes                             1,382,594           1,108,279

Other assets, net                                 2,993,901           2,934,409

Deferred licensing costs, net                     2,415,131           2,307,837

Excess of cost over net tangible
     assets acquired, net                        32,866,990          33,634,458
                                             ---------------      --------------

Total Assets                                  $ 103,147,864        $ 99,733,517
                                            ===============       ==============

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
    Current portion of borrowings under
          bank line of credit agreements        $ 1,277,327         $ 1,619,312
    Current portion of long-term debt             4,113,447           5,000,062
    Note payable to related party                 1,637,939           1,637,495
    Current portion of capital lease obligations    178,409             194,476
    Accounts payable                              9,014,732          10,039,489
    Income taxes payable                            607,307              27,739
    Accrued salaries and wages                    1,270,306           1,125,216
    Deferred income taxes                           118,280             118,280
    Other accrued liabilities                     3,303,255           2,719,496
                                             ---------------      --------------
        Total current liabilities                21,521,002          22,481,565


Long-term debt, including borrowings
     under bank line of credit agreements        30,756,959          30,747,855
Capital lease obligations                           821,246             800,117

Deferred income taxes                             3,032,812           3,024,550

Other liabilities                                 2,587,426           2,626,763

Shareholders' equity:
    Common stock, $.10 par value                    774,754             748,841
    Additional paid-in capital                   18,982,021          16,945,885
    Retained earnings                            28,157,912          25,498,721
    Accumulated other comprehensive loss         (3,486,268)         (3,140,780)
                                             ---------------      --------------

        Total shareholders' equity               44,428,419          40,052,667
                                             ---------------      --------------

Total Liabilities and Shareholders' equity    $ 103,147,864        $ 99,733,517
                                             ===============      ==============

See accompanying notes.
<PAGE>

IMMUCOR, INC.
                   Condensed Consolidated Statements of Income
                                   (Unaudited)

<TABLE>
<CAPTION>

                                                 Three Months Ended                    Six Months Ended
                                           November 30,     November 30,         November 30,     November 30,
                                               1999             1998                  1999             1998
                                          ---------------   --------------      ---------------   --------------
<S>                                             <C>              <C>                    <C>              <C>

Net sales                                    $20,249,819      $13,665,490         $39,179,786      $24,023,955
Cost of sales                                  9,268,872        6,316,043          18,223,299       10,968,726
                                           ---------------   --------------     ---------------   --------------

Gross profit                                  10,980,947        7,349,447          20,956,487       13,055,229

Research and development                         371,569          297,345             730,257          587,372
Selling and marketing                          2,912,990        2,343,582           5,920,087        4,291,329
Distribution                                   1,463,690          735,198           2,998,960        1,298,149
General and administrative                     2,858,310        2,069,043           5,239,288        3,769,533
Merger-related expenses                                -          312,361                   -          312,361
Amortization expense                             439,348          239,098             900,248          381,234
                                          ---------------   --------------      ---------------   --------------
Total operating expenses                       8,045,907        5,996,627          15,788,840       10,639,978
                                          ---------------   --------------      ---------------   --------------

Income from operations                         2,935,040        1,352,820           5,167,647        2,415,251

Interest income                                    6,098          110,901              10,615          285,933
Interest expense                                (790,192)        (252,392)         (1,439,526)        (386,479)
Other income                                      60,033           44,037             150,087           51,452
                                          ---------------   --------------      ---------------   --------------
Total other                                     (724,061)         (97,454)         (1,278,824)         (49,094)
                                          ---------------   --------------      ---------------   --------------

Income before income taxes                     2,210,979        1,255,366           3,888,823        2,366,157

Income taxes                                     770,934          539,298           1,229,632        1,022,078
                                          ---------------   --------------      ---------------   --------------

Net income                                    $1,440,045         $716,068          $2,659,191       $1,344,079
                                          ===============   ==============      ===============   ==============

Earnings per share:
   Basic                                           $0.19            $0.09               $0.35            $0.17
                                          ===============   ==============      ===============   ==============

   Diluted                                         $0.17            $0.09               $0.31            $0.17
                                          ===============   ==============      ===============   ==============

Weighted average shares outstanding:
   Basic                                       7,725,678        7,672,725           7,665,335        7,837,394
                                          ===============   ==============      ===============   ==============

   Diluted                                     8,627,333        7,939,810           8,692,140        8,111,689
                                          ===============   ==============     ===============   ==============

</TABLE>

See accompanying notes.

<PAGE>
 IMMUCOR, INC.
                 Condensed Consolidated Statements of Cash Flows
                                   (Unaudited)


                                                      Six Months Ended
                                               November 30,        November 30,
                                                   1999                1998
                                            ----------------    ----------------
OPERATING ACTIVITIES:
  Net income                                    $2,659,191           $1,344,079
  Adjustments to reconcile net income to
    net cash provided by operating activities:
      Depreciation                               1,373,395              721,694
      Amortization                                 900,248              381,234
      Changes in assets and liabilities:
        Accounts receivable                     (2,288,361)          (2,292,611)
        Accounts receivable from former
          officer and director                     140,946              552,315
        Income tax receivable                      180,033               (9,046)
        Inventories                            (1,848,289)           (1,127,536)
        Other current assets                     (247,574)              163,603
        Accounts payable                       (1,070,224)            1,643,098
        Income taxes payable                      579,568              (105,686)
        Other current liabilities                 509,612               618,935
                                          ----------------      ----------------

Cash provided by operating activities             888,545             1,890,079

INVESTING ACTIVITIES:
  Purchase of/deposits on property
      and equipment                            (1,088,497)           (1,472,477)
  Cash paid for acquisitions                     (212,204)          (25,102,864)
  Acquisition-related severance                   (79,019)           (2,116,909)
  Decrease in other assets                       (263,337)                    -
                                          ----------------      ----------------

Cash used in investing activities              (1,643,057)          (28,692,250)

FINANCING ACTIVITIES:
  Borrowings under line of credit agreements      166,172            20,600,000
  Repayment of notes payable                   (1,375,836)             (838,371)
  Exercise of stock options and warrants
    (259,131 and 167,587 shares, respectively)  2,062,049             1,259,194
  Purchase and retirement of stock
    (721,200 shares)                                    -            (6,453,961)
                                          ----------------      ----------------

Cash provided by (used in) financing activities   852,385            14,566,862

EFFECT OF EXCHANGE RATE CHANGES ON CASH           102,458               392,295
                                          ----------------      ----------------

INCREASE IN CASH AND CASH EQUIVALENTS             200,331           (11,843,014)

CASH AND CASH EQUIVALENTS AT
     BEGINNING OF PERIOD                        2,793,592            15,816,217
                                          ----------------      ----------------

CASH AND CASH EQUIVALENTS                      $2,993,923            $3,973,203
                                          ================      ================
 AT END OF PERIOD

Noncash investing and financing activities:
  Fair value of assets acquired, net of cash                        $17,757,750
  Cost in excess of assets acquired                                  16,523,461
  Liabilities assumed                                                (9,178,347)
                                                                ----------------
  Net cash paid for acquisition                                     $25,102,864

<PAGE>
 IMMUCOR, INC.
              Notes to Condensed Consolidated Financial Statements
                                   (Unaudited)


1.     BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial  information  and the  instructions  to Form  10-Q and  Article  10 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial  statements.  However,  there  has  been  no  material  change  in the
information disclosed in the Company's annual financial statements dated May 31,
1999, except as disclosed herein. In the opinion of management,  all adjustments
(consisting  of  normal  recurring  accruals)  considered  necessary  for a fair
presentation  have been  included.  Operating  results for the six month  period
ended November 30, 1999 are not  necessarily  indicative of the results that may
be expected for the year ending May 31, 2000. For further information,  refer to
the  consolidated  financial  statements and footnotes  thereto  included in the
Company's Annual Report on Form 10-K for the year ended May 31, 1999.


2.       INVENTORIES

Inventories are stated at the lower of first-in, first-out cost or market:

                                         As of                   As of
                                   November 30, 1999         May 31, 1999
                                   ------------------     ------------------
Raw materials and supplies             $5,018,557               $3,856,309
Work in process                           947,396                  967,889
Finished goods                         11,947,526               11,240,992
                                   ==================     ==================
                                      $17,913,479              $16,065,190
                                   ==================     ==================


3.     EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted earnings per
share in accordance  with Statement of Financial  Accounting  Standards No. 128,
Earnings per Share.


<TABLE>
<CAPTION>

                                                         Three Months Ended                 Six Months Ended
                                                    November 30,     November 30,     November 30,     November 30,
                                                        1999             1998             1999             1998
                                                   ---------------- ---------------  ---------------- ---------------
<S>                                                      <C>             <C>                 <C>            <C>

Numerator for basic and diluted earnings per share:
  Income available to common shareholders              $ 1,440,045       $ 716,068        $2,659,191      $1,344,079
                                                   ================ ===============  ================ ===============


Denominator:
  For basic earnings per share - weighted
  average basis                                          7,725,678       7,672,725         7,665,335       7,837,394

  Effect of dilutive stock options and warrants            901,655         267,085         1,026,805         274,295
                                                   ---------------- ---------------  ---------------- ---------------
  Denominator for diluted earnings per share -
  adjusted weighted-average shares                       8,627,333       7,939,810         8,692,140       8,111,689
                                                   ================ ===============  ================ ===============

Basic earnings per share                                     $0.19           $0.09             $0.35           $0.17
                                                   ================ ===============  ================ ===============


Diluted earnings per share                                   $0.17           $0.09             $0.31           $0.17
                                                   ================ ===============  ================ ===============

</TABLE>


<PAGE>



4.    DOMESTIC AND FOREIGN OPERATIONS

Information   concerning  the  Company's  domestic  and  foreign  operations  is
summarized below (in 000s):
<TABLE>
<CAPTION>

                                                         Three Months Ended November 30, 1999
                          ----------------------------------------------------------------------------------------------------
                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
<S>                         <C>            <C>            <C>         <C>           <C>              <C>            <C>

Net sales:
  Unaffiliated customers   $12,751        $2,757        $1,751        $1,415        $1,576      $      -         $20,250
  Affiliates                 1,731           147             -            80           949        (2,907)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                 14,482         2,904         1,751         1,495         2,525        (2,907)         20,250

Income from operations       2,024           372           168           452           (81)            -           2,935


                                                         Three Months Ended November 30, 1998
                          ----------------------------------------------------------------------------------------------------
                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
Net sales:
  Unaffiliated customers   $7,550        $2,656        $1,884        $1,029          $546      $       -        $13,665
  Affiliates                1,069            78             -            26             -         (1,173)             -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                  8,619         2,734         1,884         1,055           546        (1,173)        13,665

Income from operations         277           440           264           284            82             6          1,353


                          ----------------------------------------------------------------------------------------------------
                                                          Six Months Ended November 30, 1999
                          ----------------------------------------------------------------------------------------------------

                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
Net sales:
  Unaffiliated customers   $24,985        $4,875        $3,419        $2,497        $3,404      $      -         $39,180
  Affiliates                 3,253           248             -           151         1,329        (4,981)              -
                          ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                 28,238         5,123         3,419         2,648         4,733        (4,981)         39,180

Income from operations       3,656           598           330           719          (127)           (8)          5,168

                          ----------------------------------------------------------------------------------------------------
                                                          Six Months Ended November 30, 1998
                          ----------------------------------------------------------------------------------------------------

                            U.S.         Germany        Italy        Canada        Other        Eliminations    Consolidated
Net sales:
  Unaffiliated customers   $12,498        $5,079        $3,398        $2,216          $833       $     -         $24,024
  Affiliates                 2,047           166             -            93             -        (2,306)              -
                           ----------    ----------    ----------    ----------    ---------     ------------    --------------
      Total                 14,545         5,245         3,398         2,309           833        (2,306)         24,024

Income from operations         539           800           386           623            95           (28)          2,415

</TABLE>

The Company's U.S. operation made net export sales to unaffiliated  customers of
approximately  $1,733,000 and $1,213,000 for the three months ended November 30,
1999 and 1998,  respectively  and  $3,481,000  and $2,043,000 for the six months
ended November 30, 1999 and 1998,  respectively.  The Company's German operation
made net export sales to unaffiliated  customers of  approximately  $245,000 and
$86,000 for the three months ended November 30, 1999 and 1998,  respectively and
$495,000  and  $374,000  for the six months  ended  November  30, 1999 and 1998,
respectively.  The  Company's  Canadian  operation  made  net  export  sales  to
unaffiliated  customers  of  approximately  $560,000  and $596,000 for the three
months  ended  November  30,  1999 and 1998,  respectively  and  $1,091,000  and
$1,407,000  for the six months ended  November 30, 1999 and 1998,  respectively.
Product sales to affiliates are valued at market prices.











5.       COMPREHENSIVE INCOME

The components of comprehensive income for the three-month and six-month periods
ended November 30, 1999 and 1998 are as follows:

<TABLE>
<CAPTION>

                                              Three Months Ended                         Six Months Ended
                                      November 30,         November 30,         November 30,           November 30,
                                          1999                 1998                 1999                   1998
                                     ----------------     ----------------    ------------------     -----------------
<S>                                        <C>                 <C>                   <C>                   <C>

Net income                             $ 1,440,045             $716,068            $2,659,191            $1,344,079
Net foreign currency translation          (735,902)             777,732              (345,488)              724,045
                                     ----------------     ----------------    -----------------      -----------------

Comprehensive income                     $ 704,143           $1,493,800            $2,313,703            $2,068,124
                                     ================     ================    ==================     =================
</TABLE>

Accumulated  comprehensive  loss as of  November  30,  1999 and May 31, 1999 was
($3,486,268) and ($3,140,780),  respectively. The balance consists of net losses
on  foreign  currency  translation  adjustments  and has been  disclosed  in the
shareholders' equity section of the condensed consolidated balance sheet.


6.   CONTINGENCIES

When the Company  acquired Gamma  Biologicals,  Inc.  ("Gamma  Biologicals")  in
October 1998, Gamma Biologicals was a party to an existing legal proceeding.  On
May 12, 1998, Gamma  Biologicals  received  notification  that a claim of patent
infringement  had  been  filed on that  date in U.S.  District  Court,  Southern
District of Florida,  Miami Division, by Micro Typing Systems, Inc. and Stiftung
fur Diagnostiche Forschung (the Foundation).  Subsequently, in February 1999 the
Company received notification that a second claim was filed in the U.S. District
Court for the  Northern  District of Georgia,  against  Immucor,  Inc. and Gamma
Biologicals for patent  infringement  on the first patent  described above and a
second patent  recently  granted to the  Foundation.  The claim alleges that the
recently  introduced Gamma ReACT Test System infringes U.S. patent No. 5,512,432
granted to the Foundation April 30, 1996 and U.S. patent No.  5,863,802  granted
to the  Foundation on January 26, 1999. The  plaintiffs  seek a preliminary  and
permanent  injunction  against  the  continued  alleged  infringement  by  Gamma
Biologicals and Immucor, and an award of treble damages, with interest and costs
and reasonable  attorney's  fees.  Management is confident that ReACT technology
does not infringe the Foundation's  patents;  however, an unfavorable outcome in
this  action  could have a material  adverse  effect upon the  business  and the
results of operations in a given reporting  period.  Since this matter is in the
earliest stage of proceedings and due to  uncertainties  involved in litigation,
management  cannot  predict the likelihood of a particular  outcome.  Management
believes it has a meritorious defense against the alleged infringement.



<PAGE>

                                  IMMUCOR, INC.

ITEM 2.  Management's Discussion and Analysis of Financial Condition and Results
of Operations.

       Any  statements  contained  herein  that  are  not  historical  fact  are
forward-looking   statements  within  the  meaning  of  the  Private  Securities
Litigation  Reform  Act of  1995,  and  involve  risks  and  uncertainties.  All
forward-looking  statements  included in this document are based on  information
available  to the  Company  on the  date  hereof,  and the  Company  assumes  no
obligation  to update any such  forward-looking  statements.  Further  risks are
detailed in the Company's  filings with the Securities and Exchange  Commission,
including  those set forth in its Annual Report on Form 10-K for the fiscal year
ended May 31, 1999.

Financial Condition and Liquidity:

       During the six months ended November 30, 1999, the Company  increased its
profitability,  generated  positive cash flow from  operations,  and  maintained
positive working  capital.  As of November 30, 1999, the Company's cash position
totaled  $2,994,000.  For the three months ended  November 30, 1999, the Company
generated cash from operating activities of $889,000,  repaid $1,376,000 of bank
debt in France,  Belgium and the U.S. and  purchased  property and  equipment of
$1,088,000.  The exercise of  approximately  259,000  stock options and warrants
provided $2,062,000 in cash.

        Management believes that the Company's current cash and cash equivalents
balance,  internally  generated funds, and amounts  available under the lines of
credit should be more than  sufficient to support  operations to support planned
product  introduction  and continued  improvement  and  development  of products
during the next 12 months.  Management  also  believes  additional  credit lines
would be available should the need arise for capital improvements,  acquisitions
or other corporate purposes.

Results of Operations:

Net sales

       Net  sales  for  the  three  months  ended   November  30,  1999  totaled
$20,250,000  an  increase  of  $6,585,000  (48%) over last  year's  $13,665,000.
Current year  three-month  results  included  $4,607,000 in net sales from Gamma
Biologicals,  Inc.  ("Gamma  Biologicals")  acquired  on  October  27,  1998 and
$829,000 in net sales from Medichim and  Immunochim  acquired on March 15, 1999.
The remaining  increase in sales was generated in the U.S. and was primarily due
to net sales of  approximately  $1,200,000  from BCA,  a  division  of  Biopool,
acquired  on April 30, 1999 and  instrumentation  sales.  The Company  generated
instrument revenues of $3,589,000 for the quarter compared to $1,583,000 for the
same period last year. Sales by the Company's Canadian and European subsidiaries
combined increased 23% over last year's total excluding  acquisitions.  However,
when  translated  into US  dollars,  there  was an  increase  of only 10% due to
unfavorable  exchange  rates in Europe.  The Company's  German  subsidiary had a
slight  increase in sales of 4% due to instrument  sales but sales from its base
business  of  reagents  were down 13% when  compared  to last year.  For the six
months ended  November 30, 1999,  net sales were  $39,180,000  (including  Gamma
Biologicals' $9,660,000) compared to $24,024,000 in the prior year.

Gross profit

       As a percent of sales,  gross profit for the three months ended  November
30, 1999 totaled 54.2% versus 53.8% for the same period in 1998. The increase in
gross  profit  margin  was  primarily  caused by  increased  reagent  sales when
compared to last year.  Gross profit for the six months ended  November 30, 1999
totaled 53.5% versus 54.3% for the same period in 1998.



Operating expenses

       When  compared  to the prior  year,  three and six  month  periods  ended
November 30, 1999, research and development costs increased $74,000 and $143,000
with $57,000 additional research expenses year to date resulting from prior year
acquisitions and on-going research projects.

       Selling and marketing  expenses for the three and six month periods ended
November 30, 1999,  increased  $569,000 and  $1,629,000  as compared to the same
periods last year.  Approximately  $608,000 of the increase year to date was due
to the inclusion of prior year  acquisitions  of Gamma  Biologicals and Medichim
and Immunochim.  The remainder of the increase is primarily due to the effect of
higher payroll  expense due to additional  personnel  required for the Company's
instrumentation strategy and expansion of its Spanish operation.

       Distribution  expenses  increased $728,000 for the three month period and
$1,701,000 for the six month period of which prior year acquisitions account for
$359,000 for the quarter.  The remaining  increase relates to increased shipping
activity.

        General and administrative  expenses for the three and six month periods
increased  $789,000 and $1,470,000 with additional  expenses of $283,000 year to
date  resulting  from  the  purchase  of  Gamma  Biologicals  and  Medichim  and
Immunochim  and the  remainder  due to higher  expenses as we expand  operations
worldwide.

       Merger-related  expenses for the prior year are one-time expenses related
to the Gamma Biologicals and BCA acquisitions.

       Amortization  expense for the three and six months periods ended November
30,  1999,  increased  $200,000  and  $519,000  due to goodwill  recorded in the
acquisitions of Gamma  Biologicals on October 27, 1998,  Medichim and Immunochim
on March 15, 1999 and BCA, a division of Biopool, on April 30, 1999.

Interest income

       Interest income  decreased  $105,000 for the quarter and $275,000 for the
six month  period due to lower cash  balances as compared to last year caused by
the purchase of treasury stock and the purchase of Gamma  Biologicals  and other
acquisitions which were partially funded by the use of the Company's cash.

Interest expense

       When  compared  to the prior year three and six month  periods,  interest
expense increased  $538,000 and $1,053,000.  This is a result of the purchase of
Gamma Biologicals and other  acquisitions which were primarily financed with the
proceeds of a bank loan.

Other income

       Other income increased $16,000 for the three month period and $99,000 for
the six month  period as  compared  to the prior  year due to  foreign  currency
transaction  gains in the current  period  versus losses in the same period last
year.

Income taxes

       Income tax expense as a percent of pretax  income,  decreased  during the
three month period ended  August 31, 1999,  and six month period ended  November
30,  1999,  due to lower  taxes  provided  in Germany  and the United  States as
compared  to the  prior  period.  This  is a  result  of the  Company's  ongoing
implementation of tax planning strategies.


<PAGE>


Year 2000

       As of the date of this filing,  January 14, 1999, the Company has not yet
incurred any significant  business  disruptions as a result of year 2000 issues.
However,  while no such  occurrence has developed as of the date of this filing,
year 2000 issues that may arise related to third parties may not become apparent
immediately  and  therefore,  there is no assurance that the Company will not be
affected by third party  noncompliance in the future.  The Company will continue
to monitor the issue  diligently  and work to address any issues that may arise.
In order to become year 2000  compliant,  the  Company set up a project  team to
address the issue and has taken the following steps:

       Impact  Assessment - Instances where  electronics are used in the Company
and the associated  potential risks have been  identified.  The Company believes
that  non-information  technology systems and its products are not significantly
impacted.  However,  internal business information software was affected and the
Company has implemented program changes in order to become year 2000 compliant.

       Third Party Impact Assessment - The Company has  substantially  completed
the  verification  of the readiness of its  significant  suppliers and customers
through the distribution of a questionnaire. Based on information available, the
Company  has no reason to believe  that any year 2000  problems  encountered  by
customers  and  suppliers  will  have a  significant  effect  on  the  Company's
operations.

       Project Plan - Based on the impact assessment,  the need to make software
program changes to the Company's internal business information software has been
identified.  In Europe,  minor software program changes to existing systems have
been made at a nominal  cost making  them year 2000  compliant  before  December
1999. In North America, the Company had planned to complete  implementation of a
year 2000  compliant  enterprise  wide internal  business  information  software
system by December 31, 1999.  The Company is  continuing to implement the system
but has decided to reschedule the  operational  date of the new enterprise  wide
internal business  information  software system for March 2000.  Therefore,  the
Company's  initial  contingency  plan was put into effect under which changes to
the existing  internal business software were made making it year 2000 compliant
at a cost of approximately $20,000 which was expensed as incurred.

       The Company believes that it is diligently addressing the year 2000 issue
and expects  that  through its actions  year 2000  problems  are not  reasonably
likely to have a material adverse effect on the Company's operations.  There can
be no assurance that such problems will not arise.

ITEM 3.  Quantitative and Qualitative Disclosures About Market Risk

       There have been no material  changes  regarding the Company's market risk
position from the information provided in its Annual Report on Form 10-K for the
fiscal year ended May 31, 1999. The  quantitative  and  qualitative  disclosures
about  market  risk are  discussed  in Item  7A-  Quantitative  and  Qualitative
Disclosures About Market Risk, contained in the Company's Form 10-K.


<PAGE>

PART 11 - OTHER INFORMATION



Item 6. Exhibits and Reports on Form 8-K.
         (a) The Company has filed the following exhibits with this report:

         27 Financial data schedule.

         (b) The Company  did not file any reports on Form 8-K during the three
             months ended November 30, 1999.


<PAGE>

 SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                  IMMUCOR, INC.
                                  (Registrant)



Date:  January 14, 2000








/s/  Edward L. Gallup          Edward L. Gallup, President
-------------------------







/s/  Steven C. Ramsey          Steven C. Ramsey, Senior Vice President - Finance
-------------------------          (Principal Accounting Officer)